CytomX Therapeutics (CTMX) to Release Quarterly Earnings on Wednesday

CytomX Therapeutics (NASDAQ:CTMX) is anticipated to announce its Q1 2025 earnings results before the market opens on Wednesday, May 14th. Analysts expect CytomX Therapeutics to post earnings of $0.10 per share and revenue of $35.42 million for the quarter.

CytomX Therapeutics (NASDAQ:CTMX) last announced its quarterly earnings results on Thursday, March 6th. The biotechnology company reported $0.22 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.45. The company had revenue of $38.09 million during the quarter, compared to the consensus estimate of $13.53 million. CytomX Therapeutics had a net margin of 10.96% and a negative return on equity of 41.47%. On average, analysts expect CytomX Therapeutics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

CytomX Therapeutics Stock Performance

CytomX Therapeutics stock opened at $0.97 on Wednesday. The firm has a market capitalization of $78.52 million, a P/E ratio of 5.73 and a beta of 1.11. The company has a 50-day simple moving average of $0.64 and a 200-day simple moving average of $0.85. CytomX Therapeutics has a one year low of $0.40 and a one year high of $4.49.

Analyst Ratings Changes

CTMX has been the subject of several analyst reports. StockNews.com initiated coverage on CytomX Therapeutics in a research report on Tuesday, April 15th. They set a “hold” rating for the company. HC Wainwright reissued a “neutral” rating on shares of CytomX Therapeutics in a research note on Friday, March 7th. Wedbush reissued an “outperform” rating and set a $5.00 price target on shares of CytomX Therapeutics in a report on Friday, March 7th. Finally, Piper Sandler began coverage on shares of CytomX Therapeutics in a report on Monday, April 14th. They issued an “overweight” rating and a $2.50 price objective for the company. Three equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $3.70.

About CytomX Therapeutics

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.